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Prevalence of raised sodium-lithium countertransport activity in type 1
diabetic patients. The prevalence of raised Na/Li countertransport
(CT) activity (>0.41 mmol/liter RBC/hr) was assessed in 185 consecu-
tive insulin-dependent diabetic patients attending an outpatient diabetic
clinic. Normoalbuminuria was defined as an overnight albumin excre-
tion rate (AER) of <20 rg/min (N = 121), microalbuminuria as AER
between 20 and 150 sgImin (N = 35) and macroalbuminuria as AER 
150
.tg/min (N = 29). The prevalence of elevated Na/LiCT (>0.41
mmol/liter RBCIhr) was 21.5, 42.8 and 51.7% (P = 0.0005), in patients
with normo-, micro- and macroalbuminuria, respectively. In the whole
group, Na7LiCT was significantly related to mean blood pressure
(MBP; r = 0.37, P < 0.001) and AER (r = 0.38, P< 0.001). In a
multiple regression analysis the significant correlates ôfm&R, as a
continuous variable, or of proteinuria (micro + macroalbuminuria), as
a categorical variable, were Na/LiCT, MBP, duration of diabetes and
glycosylated hemoglobin (HbAl). The frequency of normoalbuminuric
patients with high Na1LiCT activity fell with duration of diabetes.
The risk of proteinuria was significantly greater in patients with raised
Na47LiCT compared to those with Na1LiCT within the normal
range (odds ratio 3.8, 95% CI, 1.9 and 7.8). A relative excess of patients
with proteinuria (micro + macroalbuminuria) was found in the group
with elevated Na/LiCT and HbAI above the median value (8.05%) of
the whole population (y = 9.7, P < 0.002). Elevated Na/LiCT
activity is more prevalent in IDDM patients with proteinuria and is rare
in long-standing normoalbuminuric patients; the risk of proteinuria
increases with increasing Na/LiCT rates; blood glucose control and
Na/LiCT appear to interact in determining proteinuria.
Elevated red blood cell sodium-lithium countertransport
(Na/LiCT) is associated with essential hypertension [1] and,
in type 1 (insulin-dependent) diabetes mellitus (IDDM), with
proteinuria, lipid disturbances and elevated blood pressure
[2—6J. It has been suggested that, in a subset of diabetic
individuals, raised Na/LiCT could be a marker of risk for
renal and cardiovascular complications [7], but almost all
studies to date have been in highly selected, relatively small
groups of patients. The prevalence of high Na/LiCT and its
relation to proteinuria and other risk factors for vascular
complications in larger groups of IDDM has not been reported.
In the present study we therefore assessed the prevalence of
high sodium-lithium countertransport in a group of 185 Euro-
pean IDDM patients attending a diabetic outpatient clinic,
explored the relationship of Na/LiCT with proteinuria, and
related it to other markers of risk of renal disease.
Methods
From January 1989 to January 1990, all IDDM patients aged
16 years or more, with a diagnosis of diabetes before the age of
40 years and who were free of any endocrine, liver, metabolic,
cardiac and non-diabetic renal disease and were attending the
diabetic outpatient clinic at Guy's Hospital were asked to
participate in the study. One hundred and eighty-five people
gave their informed consent to the study, which was approved
by the Ethical Committee of the Hospital.
Three timed, overnight urine collections were performed for
measurement of albumin excretion rate, in sterile specimens,
using a radioimmunoassay [8]. The median urinary albumin
excretion rate (AER) value was used for classifying the patients
as normoalbuminuric (AER < 20 Lg/min, N = 121); microal-
buminuric (AER  20 and < 150 g/min, N = 35); and
macroalbuminuric (AER  150 g/min, N = 29). Their clinical
features are shown in Table 1. Sixteen (55%) of the patients
with macroalbuminuria and 15 (43%) of those with microalbu-
minuria were taking antihypertensive drugs, including /3-block-
ers, calcium antagonists, angiotensin converting enzyme inhib-
itors, vasodilators, and thiazide and loop diuretics. Two
patients classified as microalbuminuric were formerly macroal-
buminuric, now on treatment with low protein diet and capto-
pril, but with GFR values of 39 and 40 ml/min/1.73 m2,
respectively.
All antihypertensive drugs were discontinued for at least 36
hours before the study. All other patients were not taking any
drug except insulin, and none of the females were pregnant or
on contraceptive or estrogen treatment. None had clinical
evidence of thyroid disease.
Patients were asked to attend a metabolic ward between 8:30
and 9:00 a.m. after an overnight fast. Their morning insulin
injection and breakfast were withheld until after the procedure.
Patients were weighed in indoor clothing without shoes, and
their height was measured. Blood pressure (phase I/V) was
measured twice, with patients in the supine position, by a single
observer (JBLF), at two minute intervals, to the nearest 2 mm
Hg, after a five minute rest, using a random zero sphygmoma-
nometer (Hawksley and Sons Ltd., Lancing, UK). Mean blood
pressure was calculated as diastolic blood pressure + 1/3 pulse
pressure. The average of the two readings was used for calcu-
lation. A blood sample was taken for measurements of glycated
hemoglobin (HbA I) by electroendosmosis (Corning Chemical,
Palo Alto, California, USA: normal range 5.0 to 7.6%) and of
red blood cell sodium-lithium countertransport activity by the© 1992 by the International Society of Nephrology
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Table 1. Clinical features of 185 consecutive, type 1 insulin-dependent diabetic (IDDM) patients, classified as having normoalbuminuria
(group 1, N = 121), microalbuminuria (group 2, N = 35) and macroalbuminuria (group 3, N= 29)
Group I Group 2 Group 3
Number (M/F) 75/46 23/12 15/14
Age years 33.6 (17—61) 33.7 (16—57) 36.9 (19—61)
Duration of IDDMC years 13.9 (1—40) 17.5 (5—36) 21.6 (951)
Body mass index kg/rn2 25.1 (18,6—31.2) 24.4 (19.0—28.9) 24.1 (18.6—30.9)
MBPb mm Hg 91.7 (7 1—130) 101.7 (72—144) 101.3 (83—126)
HbAl % 8.1 (4.0—12.8) 7.9 (4.2—12.0) 9.4 (5.7—13.5)
GFRd mI/min/J.73 m2 117.4 (74—159) 114.2 (39—147) 65.0 (15—125)
AER ,sg/mine 6.6 (0.9—19. 1) 38.9 (20.6—135.0) 683.9 (150.7—4927.0)
Abbreviations are: MBP, mean blood pressure; GFR, glomerular filtration rate; AER, albumin excretion rate; Data are mean (range).
a P = 0.0001, group 1 vs. group 3
b P C 0.0001, group I vs. group 2 and group 3
a P = 0.0036, group 3 vs. group 1 and group 2d p C 0.0001, group 3 vs. group 1 and group 2
C Geometric mean (range)
method of Canessa et al [1], as previously reported by our
laboratory [3] (normal range 0.11 to 0.41 mmol/liter RBC/hr, as
determined in 35 normotensive subjects with negative family
history of hypertension). Glomerular filtration rate (GFR) was
measured by plasma clearance of 51Cr-EDTA using a multiple
exponential analysis of the tracer decay curve, as previously
described [91, either on the same day or within three months of
the study, and results were expressed in mllmin/1.73 m2. All
measurements were performed in ignorance of the patient's
clinical status and urinary albumin excretion rate.
Statistical analysis
One-way analysis of variance and Tukey's test were used for
comparison of parametric data between different groups.
Kruskall-Wallis ANOVA was employed for analysis of not
normally distributed data. Simple correlations of sodium-lith-
ium countertransport activity with different variables were
assessed by Spearman's rank correlation. Because of the inter-
relationship of several variables, univariate analysis was fol-
lowed by multiple regression analysis with log-transformed
albumin excretion rate or the category proteinuria (micro +
macroalbuminuria) as the dependent variable. Chi-square test
with Yates' continuity correction was used to compare discrete
variables.
Mantel-Haenszel's summary odds ratio with Miettinen's test-
based 95% confidence intervals were calculated [10] in order to
estimate the risk of proteinuria in patients with normal or raised
Na/LiCT.
Results are mean 5EM unless otherwise stated. P values C
0.05 were considered to be significant.
Results
The prevalence of microalbuminuria and macroalbuminuria
in this group of 185 clinic based IDDM patients was 18.9% and
15.7%, respectively. Micro- and macroalbuminuric diabetic
patients had similar age and BMI to the normoalbuminuric
patients, but had longer duration of diabetes. Mean blood
pressure was similar in micro- and macroalbuminuric patients,
and significantly higher when compared to the normoalbumin-
uric group. Macroalbuminuric patients had higher HbA 1 and
lower glomerular filtration rate compared to the other two
groups (Table I).
The overall prevalence of elevated Na/LiCT (that is, >
0.41 mmol/liter RBC/hr) was 3 1.2%. Median NC/LiP CT was
significantly higher in the microalbuminuric (0.40 mmol/liter
RBC/hr) and macroalbuminuric (0.42 mmol/liter RBC/hr) than
in the normoalbuminuric diabetics (0.29 mmollliter RBC/hr; P
C 0.005; Fig. 1). Moreover, the prevalence of elevated Na/
LiCT was significantly and similarly higher in the microalbu-
minuric (42.8%) and macroalbuminuric patients (51.7%) com-
pared to the normoalbuminuric group (21.5%; P 0.0005).
Figure 2 shows the relationship between AER and quartiles
of Na/LiCT activity (C 0.20, C 0.27,  0.38, > 0.38
mmollliter RBC/hr). The percentage of patients with micro- or
macroalbuminuria significantly increased as Na/LiCT rose
= 20.2, P = 0.0025), while that of normoalbuminuric
patients declined from 86% to 46.2%.
In the whole group, Na/LiCT in a univariate regression
analysis correlated significantly with mean blood pressure (r =
0.37, P C 0.001), and albumin excretion rate (r = 0.38, P C
Tl.OOl), but no correlations were found with glycated hemoglo-
bin, age, duration of diabetes, body mass index or GFR. In
particular in the normoalbuminuric group, Na/LiCT was not
correlated with GFR, and there were no differences in GFR
between normoalbuminuric patients with high or normal Na/
LiCT (GFR 117 3 vs. 118 4 ml/min/l.73 m2, respectively,
P 0.79).
Because several of the variables considered were signifi-
cantly interrelated in the univariate analysis (AER with MBP,
duration of DM and Na/LiCT; MBP with BMI; duration with
age; Nat'LiCT with MBP), a stepwise multiple regression
analysis was carried out with AER as the dependent variable.
Duration of diabetes, MBP, HbAI and Na/LPCT were the
only variables which correlated significantly with AER (Table
2). In this model, the variation in Na/LiCT explains 15% of
the variation in AER; duration accounts for 7%; MBP explains
5%; and HbA1 is approximately 3% (Table 2).
When the dependent variable AER was treated as a category
of proteinuria negative or positive (that is, AER C 20 g/min or
AER  20 pg/mm), once again duration of diabetes (P
0.0001), MBP (P = 0.001) and Na/LiCT (P = 0.0125)
appeared as significant determinants of the outcome; in this
model, HbA1 just failed to reach statistical significance (P
0.06).
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Quartiles of Na/LiCT
Fig. 1. Rates of red blood cell sodium-lithium
counlertransport (Na/LiCT) in IDDM
patients with normoalbuminuria (N = 121),
microalbuminuria (N = 35) and
macroalbuminuria (N = 29). The dashed line
indicates the upper limit of normal in our
laboratory (0.41 mmol/liter RBC/hr). Solid
lines indicate median values.
LiCT activity ( = 2.76, P = 0.1), even though there was a
much higher percentage of normoalbuminuric (75%) than pro-
teinuric (25%) patients in the group with normal rates of
Na/LiCT. By contrast, in the group with HbA1 above the
median, there was a marked and significant ( 9.7, P <
0.002) excess of patients with proteinuria among the group with
increased Na7LiCT activity (Fig. 3). In patients with normal
Na/LiCT the relative frequency of proteinuria was similar
independently of the HbA1 category. These findings strongly
suggest an interaction between blood glucose control and
Na/LiCT as determinant of proteinuria.
Normoalbuminuric patients had a significantly shorter dura-
tion of diabetes than the other two groups and are likely to
contain a significant proportion of individuals who will eventu-
ally progress to proteinuria. Analysis of data was therefore
performed after stratification for duration of diabetes. The
percentage of high Na/LiCT declined in normoalbuminuric
N. patients as the duration of diabetes increased, from 29.3% for
patients with less than 10 years duration to 15% for patients
with more than 20 years of duration (Fig. 4A) By contrast, there
was no significant change with duration of diabetes in the
percentage of proteinuric (micro + macro) patients with ele-
vated Na/LiCT which varied from approximately 40 to 60%
(Fig. 4B). The proportion of patients with elevated Na/LiCT
among proteinuric subjects was significantly higher than among
normoalbuminuric diabetics after 20 years duration of disease( = 7.6, P = 0.0057). These data indicate that elevated rates
of Na4 /LiCT are infrequently found in long-term normoalbu-
minuric patients.
In the whole group, the odds of having proteinuria for
patients with an elevated Na/LiCT was 3.8 times greater
(95% CI 1.9 and 7.8), when controlling for duration of diabetes,
and this risk rose markedly for longer-term diabetic patients
(that is, those of more than 20 years of duration) (odds ratio 6.9,
95% CL 2.6 and 19.2).
To further dissect the relationship between Na/LiCT,
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Fig. 2. Percentage of patients with normo-, micro- and macroalbumin-
uria in each quartile of the distribution of Na/Li CT. Open, hatched
and cross-hatched bars represent the percentage of normo-, micro- and
macroalbuminuric patients, respectively.
To further analyze the interaction between HbA1 and Na/
LiCT in relation to AER, patients were divided into two
groups with HbA1 below or above the median (8.05%) of the
distribution for the whole group and the prevalence of protein-
uria (micro + macro, that is, AER  20 ig/min) related with a
high or normal Na/LiCT. In the group with HbA1 below the
median the frequency of normoalbuminuric and proteinuric
patients did not significantly change with changes in Na/
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Table 2. Stepwise multiple linear regression analysis with AER as dependent variable
Variable Bivariate R2 Adjusted R2 /3 T
Significance
of T
Na/Li CT
Duration of DM
Mean blood pressure
HbAl
0.15
0.11
0.11
0.02
0.15
0.22
0.27
0.30
0.24292
0.26668
0.29580
0.29377
3.249
3.869
3.838
2.859
0.0014
0.0002
0.0002
0.0049
Age (P = 0.2789) and BMI (P 0.1418) were not maintained in the equation.
Fig. 3. Frequency of normoalbuminuria (open bars) and proteinuria
(micro + macroalbuminuria) (hatched bars) in patients with normal (
0.41 mmol/liter RBC/hr) and high (> 0.41 mmol/liter RBC/hr) sodium-
lithium countertransport (Na/LiCT), divided according to HbAJ
values below or above the median.
AER and arterial pressure, the correlation between Na/LiCT
and AER was analyzed within tertiles of MBP. In the lower
tertile of MBP there was not significant correlation between
Na/LiCT and AER, but the relationship became significant in
the second and third tertiles of MBP (r = 0.29, P = 0.02 and r
= 0.28, P = 0,03, respectively). These results support the view
that the association of Na/LiCT with AER is partly depen-
dent on arterial pressure.
Discussion
The sample of IDDM patients analyzed is likely to be
representative of a diabetic clinic population in so far as the
proportion of micro- and macroalbuminuric patients was similar
to that reported by other workers in larger diabetic clinic-based
surveys 1111. In population studies, however, these proportions
have been reported to be lower [12, 13], a finding which may
reflect selection bias due to referral to specialized centers.
The prevalence of raised Na/LiCT differed markedly be-
tween insulin-dependent diabetic (IDDM) patients with nor-
moalbuminuria (21.5%) and patients with microalburninuria
(42.8%) or macroalbuminuria (51.7%). No significant difference
was found in the frequency of high Na/LiCT between
patients with microalbuminuria, a group at risk of overt renal
disease [8, 14], and those with macroalbuminuria, a group with
established renal disease.
Factors such as weight, pregnancy and thyroid disease [15—
17] which could affect Na/LiCT activity were similar among
Fig. 4. Prevalence of normal ( 0.41 mmol/liter RBC/hr) (open bars)
and elevated (> 0.41 mmol/liter RBC/hr) Na/LiCT (hatched bars) in
normoalburninuric (AER <20 /sg/min) patients (A), and in proteinuric(AER  20 j.g/min) patients (B), in relation to duration of diabetes.
the three groups, and are unlikely to have contributed to these
differences. Anti-hypertensive treatment can affect AER, and
its discontinuation for 36 hours may not have been sufficient to
eliminate its effect. Despite this, significant relationships were
found between BP and Na/LiCT and AER. Moreover, no
patient on anti-hypertensive treatment was normoalbuminuric,
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and the significant determinants of proteinuria remained the
same whether AER was treated as a continuous or a categorical
variable. Anti-hypertensive therapy is unlikely to have affected
Na/LiCT activity, even though the information available is
limited and restricted to certain classes of anti-hypertensive
drugs [18, 19]. Lipid levels were not determined in our patients
and the possibility that abnormalities in lipid concentrations,
which are known to occur in micro- and macroalbuminuric
patients [20, 21], may have contributed to differences in Na/
LiCT and cannot be entirely ruled out. An association be-
tween Na/LiCT activity and plasma lipid levels has been
described in IDDM patients with AER ranging from normo- to
microalbuminuria [5], but the cause-effect or concomitant na-
ture of this relationship remains an unresolved question.
The risk of having proteinuria (micro- and macroalbuminuria)
was approximately four times greater in patients with high
Na/LiCT in the whole group. When duration of diabetes, an
independent correlate of AER, was taken into account, the
odds of being proteinuric increased to approximately sevenfold
for patients with 20 or more years of disease. This was because
the number of normoalbuminuric patients with high Na/LiCT
markedly fell with increasing duration of diabetes. These data
are consistent with the view that elevated Na/LiCT is not a
feature of long-term uncomplicated IDDM patients, and that
many patients with high Na/LiCT would progress to protein-
uria. Short-term normoalbuminuric patients are bound to in-
clude a proportion of progressors to nephropathy, and this
might explain the higher prevalence of Na/LiCT in this
group. A prevalence of 33% of raised Na/LiCT has been
reported by other authors [22] in 52 normoalbuminuric patients
with duration of diabetes ranging from 1 to 29 years. No
adjustment for duration was made in this study. If one accepts
that only roughly 35% of IDDM patients develop nephropathy
and that approximately 50% of these have raised Na/LiCT,
the expected percentage of all durations of normoalbuminuric
patients with high Na/LiCT would be approximately 18%, a
figure close to our observation of 21.5%.
In the whole group both Na/LiCT and blood pressure (BP)
were significantly correlated with AER. Na/LiCT and mean
blood pressure were, in addition, related to each other, as
previously reported in the general population [23] and in hyper-
tensive patients [24]. Recent studies in non-diabetic subjects
suggest that the association is independent of the effect of
gender, age, body mass index and plasma lipids and indicate, in
prospective observations, that normotensive subjects who
carry the recessive major gene for high Na/LiCT have an
approximate five-fold risk of developing hypertension [23, 25].
The present study could not establish an effect of Na/LiCT
on AER separate from that of BP in that only with increasing
BP did the relationship between Na/LiCT and AER become
significant. Glycated hemoglobin emerged as a significant de-
terminant of AER, interacting with Na/LiCT to enhance the
risk of proteinuria. A relative excess of proteinuric patients was
seen in the group with higher glycated hemoglobin among those
with elevated Na/LiCT. This finding supports the view that it
is among the patients with poor control that raised Na/LiCT
significantly increases the risk of proteinuria, as previously
suggested by other workers [4]. Alternatively, poor control may
result from some abnormality associated with raised Na/
LiCT, which could independently confer a risk of vascular
complications. Recent studies have reported that hypertensive
[26] and diabetic patients [27] with elevated Na/LiCT have
increased insulin resistance, a condition which is believed to
contribute to vascular damage [28—30].
In the present study no association was found between levels
of Na/LiCT activity and GFR in normoalbuminuric patients,
which is at variance with a recent report by other workers [22].
In the study by Can- et al, however, GFR was measured in a
small subset of 18 out of 52 patients with no clear indication of
the selection procedure applied [22]. More recently, the same
group reported no association between elevated GFR and
raised Na/LiCT [31]. The significance of elevated Na/
LICT as a marker of progression of renal disease needs to be
addressed by longitudinal studies.
It is unclear how an elevation of Na/LiCT could predis-
pose diabetic patients to renal disease. Part of the risk for
nephropathy conferred by elevated Na/LiCT is likely to be
mediated through changes in BP and the risk appears magnified
by a background of poor metabolic control. Recent studies [32,
33, 34] in non-diabetic subjects suggest that elevated rates of
Na/LiCT relate to an increased prevalence of cardiovascular
complications, and, indeed, diabetic patients with proteinuria
have a significantly raised incidence of cardiovascular disease
[35, 36]. In patients with either essential hypertension or
diabetes and hypertension, higher rates of Na/LiCT have
been found to be associated with risk markers of cardiovascular
disease such as hypertriglyceridemia, microalbuminuria and left
ventricular hypertrophy [6, 37], Thus higher Na/LiCT ap-
pears to be a marker of some process responsible for renal and
cardiovascular disease. The nature of this process remains to be
elucidated, but both hemodynamic and hypertrophic factors
have been suggested as possible determinants [7]. It should be
noted that a sizable proportion ('=40%) of insulin-dependent
diabetic patients who develop proteinuria do not have elevated
Na/LiCT rates. This clearly suggests that the development of
proteinuria is a multifactorial process in which different mech-
anisms are likely to operate. The contribution of duration of
diabetes, blood glucose control, Na/LiCT and blood pres-
sure leave part of the phenomenon "proteinuria" unexplained.
Other unidentified factors not measured in this study, such as
lipids, must make an independent contribution. It may be that
elevated Na/LiCT is not exclusively an indicator of risk of
proteinuria, but more specifically is a marker of those processes
responsible for the association between nephropathy and car-
diovascular disease. This suggestion, as well as the predictive
power of high Na/LiCT for renal failure needs to be con-
firmed by prospective studies.
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